Carisma Therapeutics (NASDAQ:CARM) Receives Buy Rating from D. Boral Capital

Carisma Therapeutics (NASDAQ:CARM)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a report released on Monday,Benzinga reports. They currently have a $12.00 price objective on the stock.

Other equities research analysts also recently issued research reports about the stock. EF Hutton Acquisition Co. I raised shares of Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th. Evercore ISI reaffirmed an “in-line” rating and set a $0.70 price objective (down previously from $4.00) on shares of Carisma Therapeutics in a research note on Wednesday, December 11th. HC Wainwright reissued a “neutral” rating on shares of Carisma Therapeutics in a research note on Monday, December 16th. BTIG Research downgraded Carisma Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, December 10th. Finally, Baird R W cut Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Five research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $4.94.

Carisma Therapeutics Stock Up 3.8 %

NASDAQ:CARM opened at $0.45 on Monday. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 1.39. Carisma Therapeutics has a 12-month low of $0.38 and a 12-month high of $2.77. The stock’s fifty day simple moving average is $0.68 and its 200-day simple moving average is $0.93. The firm has a market capitalization of $18.99 million, a P/E ratio of -0.29 and a beta of 1.56.

Carisma Therapeutics (NASDAQ:CARM) last issued its earnings results on Thursday, November 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.31). The firm had revenue of $3.39 million for the quarter. Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. Equities research analysts expect that Carisma Therapeutics will post -1.32 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Barclays PLC raised its position in Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after buying an additional 549,290 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Carisma Therapeutics during the 2nd quarter worth approximately $40,000. Finally, Wexford Capital LP grew its stake in shares of Carisma Therapeutics by 75.5% during the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after acquiring an additional 15,000 shares in the last quarter. 44.27% of the stock is owned by institutional investors and hedge funds.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.